Chinese Hamster Ovary, or CHO cells, make roughly 70 percent of all F.D.A. approved biologics sold on the market. This includes bestsellers like Humira®, used to treat Crohn’s and rheumatoid arthritis, and Keytruda®, a cancer therapy. Despite their ubiquity in the pharmaceutical

A landmark study published in nature by Aaron Ring et al. has revealed that autoantibodies — immune proteins traditionally associated with autoimmune disease — may profoundly influence how cancer patients respond to immunotherapy. bit.ly/4o4HANS

Excited to share this new work from our lab, led by an exceptional graduate student, Tornike Mamuladze (Tornike Mamuladze), on the role of meningeal mast cells in regulation of brain/dura access points, with implications to CSF flow dynamics and meningitis || authors.elsevier.com/sd/article/S00…

Published today our new LAG-3 paper Cell. My group #JasperDu #JiaYou and collaborators revealed a key role of TCR proximity in LAG-3’s inhibitory function and developed LAG-3/TCR BiTS to effectively inhibit LAG-3+ T cells. dlvr.it/TLhkv7

The Weill Cancer Hub is fostering groundbreaking UC San Francisco–Stanford University collaborations to develop transformative cancer therapies. I’m grateful to co-lead one of the selected teams with Michael Fischbach to advance next-generation in vivo CAR T cell therapy!

I am super excited to announce that I will be starting my lab at the Department of Pharmacology of the University of Zurich in Switzerland next year!

BREAKING: We uncovered a potent immune alliance that could change how we treat solid tumors. Published in Cancer Cell , we show that Th17 cells *must* work with B cells to eliminate tumors—and keep it from coming back. 📄 cell.com/cancer-cell/fu… 🧵1/12👇Let’s walk through it:

Excellen nanomolar peptide binder design success rates with BindCraft!

This month, the Big Ten Cancer Research Consortium highlights our member institution Fred Hutch Cancer Center Cancer Center and Lawrence Fong, MD, who serves as scientific director of the Immunotherapy Integrated Research Center at Fred Hutch. Read more: bigtencrc.org/member-feature…

Clone tracing T cell responses in cancer (using TCR-seq methods) has been incredibly valuable for understanding immunotherapy response and opportunities. A holy grail for us has been thinking about to achieve this for innate immune responses in human cancer - with high accuracy

Martin is a breakout star in the AI-powered protein design space. He led the effort to create BindCraft and he's just getting started. I can't think of a better lab to do a post-doc or contribute as professional research staff if you want to get into this space.

Could the same proteins that drive autoimmune disease help fight cancer? In nature, Emerging Leader Award winner Aaron Ring of @FredHutch shows that some autoantibodies are linked to better outcomes for patients receiving checkpoint inhibitor therapies. fredhutch.org/en/news/releas…

CAR-T cells against solid tumors. Listen to Sabah Öney on The Long Run. timmermanreport.com/2025/08/car-t-…

BindCraft isn't just for miniproteins. A new preprint validates 47-67% success rates for BindCraft-derived peptides with nM affinities. Our tutorial with Martin Pacesa covers this work and walks through our new dedicated peptide interface. Read it here: ariax.bio/resources/bind…

I'm now the proud owner of a bespoke, handcrafted 96 well magnetic separator designed by my Twitter BFF Adriano Aguzzi. Thanks a million!!!